author-photo

Sergey Efuni

Princeton University

9

Papers

6

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis – Preliminary Data

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1368: Population pharmacokinetic-pharmacodynamic analysis of KHK2455 in patients with locally advanced or metastatic solid tumors

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis – Update of Clinical and Translational Data from the Ongoing Manifest Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis

2020
Show All
- Source
- Cite
- Save
Citations (0)
Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis

2020
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT238: An open-label, phase 1 study of IDO inhibitor KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)